In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Kenneth Thorpe, from Emery University in Atlanta, and his colleagues found in a study carried out in the USA, that while the overall number of bacterial infections remained relatively constant between 2002 and 2014, rising from 13.5 million to 14.3 million annually, the proportion that were antibiotic-resistant rose dramatically, from 5.2% to 11.0%. Patients with antibiotic-resistant infections had spending for bacterial infection that was 165 percent higher than spending by patients without such infections. Sixty-one percent of antibiotic-resistant infections were associated with urinary tract infections. Their conclusion is that the direct costs and the mortality and morbidity attributable to antibiotic-resistant infections make a compelling case for urgent action by national and international policy makers.
Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia.
Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In Russia, Adiarin® has been granted local marketing authorization as class II medical device.
We are pleased to announce that we are expanding the international coverage of our products thanks to the recent signature of agreements with both new and loyal partners. These new partnerships further enable us to spread our global footprint.
Soon you will be able to find our products in the following territories:
Ukraine - Utipro® Plus (PHARM. FABRIK MONTAVIT GmbH)
Lebanon – Aprotecol®, Gelsectan® and Xilaplus® (SPEPHAL S.A.L.)
Romania and Greece – Gelsectan® (GALENICA, S.A.)
Israel - Gelsectan®, Aprotecol® and Tasectan® Duo (LAPIDOT MEDICAL).
South Africa - Aprotecol®, Utipro® Plus (CAMOX PHARMACEUTICALS Pty Ltd.)
Hungary – Tasectan® (ELVAPHARMA s.r.o.)
Extending our collaboration with these valuable partners helps us to fulfill the mission to bring our innovative solutions to patients around the world.
For further information about our products click here: http://noventure.com/products